Список литературы к главе 3

1. Global Report on Diabetes // World Health Organization: [site]. URL: https://www.who.int/publications/i/item/9789241565257 (date of access: 05.08.2022).

2. Дедов И.И., Шестакова М.В., Майоров А.Ю., Викулова О.К., Галстян Г.Р. и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом // Сахарный диабет. 2019. Т. 22, № 1S. C. 42–114.

3. Боровик Н.В., Потин В.В., Рутенбург Е.Л. Диабетические микрососудистые осложнения (ретинопатия и нефропатия) и беременность // Журнал акушерства и женских болезней. 2013. Т. LXII, вып. 2. С. 75–82.

4. Айламазян Э.К., Абашова Е.И., Коган И.Ю. и др. Сахарный диабет и репродуктивная система женщины: руководство для врачей. Москва: ГЭОТАР-Медиа, 2019. 432 с.

5. Толпыгина М.Г., Абашова Е.И., Боровик Н.В., Тиселько А.В. Патогенез нарушения функции яичников у женщин с сахарным диабетом 1-го типа // Журнал акушерства и женских болезней. 2018. Т. 67, № 1. С. 5–12. DOI: 10.17816/JOWD6715-12.

6. Deltsidou A., Lemonidou C., Zarikas V., Matziou V., Bartsocas C.S. Oligomenorrhoea in adolescents with type 1 diabetes mellitus: relationship to glycaemic control // Eur. J. Obstet. Gynecol. Reprod. Biol. 2010. Vol. 153. P. 62–66.

7. Vlassara H., Cai W., Crandall J., Goldberg T., Oberstein R., Dardaine V. et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy // Proc. Natl. Acad. Sci. USA. 2002. Vol. 99. P. 15596–15601.

8. Brownlee M. Glycosylation products as toxic mediators of diabetic complications // Annu. Rev. Med. 2005. Vol. 42. P. 159–166.

9. Fishman S.L., Sonmez H., Basman C., Singh V., Poretsky L. The role of advanced glycation end products in the development of coronary artery disease in patients with and without diabetes mellitus: a review // Mol. Med. 2018. Vol. 24, N 1. P. 59. DOI: 10.1186/s10020-018-0060-3.

10. Testa R., Bonfigli A.R., Prattichizzo F., La Sala L., De Nigris V., Ceriello A. The «Metabolic Memory» theory and the early treatment of hyperglycemia in prevention of diabetic complications // Nutrients. 2017. Vol. 9, N 5. P. 437. DOI: 10.3390/nu9050437.

11. Ансари Н.А., Рашид З. Неферментативное гликирование белков: от диабета до рака // Биомедицинская химия. 2010. Т. 56, № 2. С. 168–178.

12. Haucke E., Navarrete Santos A., Simm A., Henning C., Glomb M.A., Gürke J. et al. Accumulation of advanced glycation end products in the rabbit blastocyst under maternal diabetes // Reproduction. 2014. Vol. 148, N 2. P. 169–178.

13. Diamanti-Kandarakis E., Piperi C., Patsouris E., Korkolopoulou P., Panidis D., Pawelczyk L. et al. Immunohistochemical localization of advanced glycation end-products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries // Histochem. Cell Biol. 2007b. Vol. 127. P. 581–589.

14. Merhi Z. Advanced glycation end products and their relevance in female reproduction // Hum. Reprod. 2014. Vol. 29, N 1. P. 135–145.

15. Takahashi N., Harada M., Azhary J.M.K., Kunitomi C., Nose E., Terao H. et al. Accumulation of advanced glycation end products in follicles is associated with poor oocyte developmental competence // Mol. Hum. Reprod. 2019. Vol. 25, N 11. P. 684–694. DOI: 10.1093/molehr/gaz050.

16. Kalea A.Z., Schmidt A.M., Hudson B.I. RAGE: a novel biological and genetic marker for vascular disease // Clin. Sci. (Lond). 2009. Vol. 116. P. 621–637.

17. Inagi R. Inhibitors of advanced glycation and endoplasmic reticulum stress // Methods Enzymol. 2011. Vol. 491. P. 361–380.

18. Piperi C.P.E., Koutsilieris M., Diamanti-Kandarakis E. Advanced glycation end products inhibit insulin signaling in human granulosa cells: A causative link to PCOS pathogenesis. San Francisco, CA: Endocrine Society, 2013.

19. Ambroggio J., Casson P., Merhi Z. Soluble Receptor for advanced glycation end products (sRAGE): a potential indicator of ovarian response to controlled ovarian hyperstimulation. Boston, MA: American Society for Reproductive Medicine, 2013.

20. Wang B., Hao M., Yang Q., Li J, Guo Y. Follicular fluid soluble receptor for advanced glycation endproducts (sRAGE): a potential protective role in polycystic ovary syndrome // J. Assist. Reprod. Genet. 2016. Vol. 33, N 7. P. 959–956.

21. Rønnekleiv O.K., Qiu J., Kelly M.J. Arcuate kisspeptin neurons coordinate reproductive activities with metabolism // Semin. Reprod. Med. 2019. Vol. 37, N 3. P. 131–140. DOI: 10.1055/s-0039-3400251.

22. Liu X., Yeo S.H., McQuillan H.J., Herde M.K., Hessler S., Cheong I. et al. Highly redundant neuropeptide volume co-transmission underlying episodic activation of the GnRH neuron dendron // Elife. 2021. Vol. 10. P. e62455. DOI: 10.7554/eLife.62455.

23. Amin R., Schultz C., Ong K., Frystyk J., Dalton R.N., Perry L. et al. Low IGF-I and elevated testosterone during puberty in subjects with type 1 diabetes developing microalbuminuria in comparison to normoalbuminuric control subjects: the Oxford Regional Prospective Study // Diabetes Care. 2003. Vol. 26. P. 1456–1461.

24. Samara-Boustani D., Colmenares A., Elie C., Dabbas M., Beltrand J., Caron V. et al. High prevalence of hirsutism and menstrual disorders in obese adolescent girls and adolescent girls with type 1 diabetes mellitus despite different hormonal profiles // Eur. J. Endocrinol. 2012. Vol. 166. P. 307–316.

25. Azhary J.M.K., Harada M., Kunitomi C., Kusamoto A., Takahashi N., Nose E. et al. Androgens increase accumulation of advanced glycation end products in granulosa cells by activating ER stress in PCOS // Endocrinology. 2020. Vol. 161, N 2. P. bqaa015. DOI: 10.1210/endocr/bqaa015.

26. Christakou C., Piperi C., Livadas S., Marinakis E., Kollias A., Katsikis I. et al. Effect of pharmaceutical intervention on serum advanced glycated end products levels in women with polycystic ovary syndrome. San Francisco, CA: Endocrine Society, 2013.

27. Schweiger B.M., Snell-Bergeon J.K., Roman R., McFann K., Klingensmith G.J. Menarche delay and menstrual irregularities persist in adolescents with type 1 diabetes // Reprod. Biol. Endocrinol. 2011. Vol. 6, N 9. P. 61.

28. Auchus R.J. The physiology and biochemistry of adrenarche // Endocr. Dev. 2011. Vol. 20. P. 20–27.

29. Codner E., Escobar-Morreale H.F. Clinical review: hyperandrogenism and polycystic ovary syndrome in women with type 1 diabetes mellitus // J. Clin. Endocrinol. Metab. 2007. Vol. 92. P. 1209–1216.

30. Gaete X., Vivanco M., Eyzaguirre F.C., López P., Rhumie H.K., Codner E. Menstrual cycle irregularities and their relationship with HbA1c and insulin dose in adolescents with type 1 diabetes mellitus // Fertil. Steril. 2010. Vol. 94. P. 1822–1826.

31. Escobar-Morreale H.F., Belén M.R.-M. Type 1 diabetes and polycystic ovary syndrome: systematic review and meta-analysis // Diabetes Care. 2016. Vol. 39, N 4. P. 639–648. DOI: 10.2337/dc15-2577.

32. Diamanti-Kandarakis E., Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications // Endocr. Rev. 2012. Vol. 33, N 6. P. 981–1030. DOI: 10.1210/er.2011-1034.

33. Мишарина Е.В., Тиселько А.В., Ярмолинская М.И., Коган И.Ю., Абашова Е.И., Боровик Н.В. Экстракорпоральное оплодотворение как метод лечения бесплодия у женщин с сахарным диабетом 1-го типа // Сахарный диабет. 2018. Т. 21, № 5. С. 425–430. DOI: 10.14341/DM9573.

34. Boinpally T., Jovanovic L. Management of type 2 diabetes and gestational diabetes in pregnancy // Mt. Sinai. J. Med. 2009. Vol. 76, N 3. P. 269–280. DOI: 10.1002/msj.20115.

35. Schwartz N., Green M.S., Yefet E., Nachum Z. Postprandial glycemic control during gestational diabetes pregnancy predicts the risk of recurrence // Sci. Rep. 2018. Vol. 8, N 1. P. 6350. DOI: 10.1038/s41598-018-24314-1.

Капустин Р.В., Аржанова О.Н., Беспалова О.Н. Экзогенный прогестерон как фактор развития гестационного сахарного диабета // Российский вестник акушера-гинеколога. 2019. Т. 19, № 1. С. 38–45.

36. Areeruk W., Phupong V. A randomized, double blinded, placebo controlled trial of oral dydrogesterone supplementation in the management of preterm labor // Sci Rep. 2016. Vol. 6. P. 20638. https://doi.org/10.1038/ srep20638.

37. Pustotina O. Efectiveness of dydrogesterone, 17-OH progesterone and micronized progesterone in prevention of preterm birth in women with a short cervix // J. Matern. Fetal. Neonatal. Med. 2018. Vol. 31, N 14. P. 1830–1838. https://doi.org/10.1080/14767058.2017.1330406.

38. Зайцева М.А. Роль прогестагенов в лечении невынашивания беременности I триместра: автореф. дис. … канд. мед. наук. СПб., 2018. 24 с.

39. Schindler A.E. Progestational effects of dydrogesterone in vitro, in vivo and on the human endometrium // Maturitas. 2009. Vol. 65. Suppl1. P. 3–11. Epub 2009 Dec 6. https://doi.org/10.1016/j.maturitas.2009.10.011.

40. Rode L., Klein K., Nicolaides K.H., Krampl-Bettelheim E., Tabor A. Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo-controlled trial on the effect of vaginal micronized progesterone // Ultrasound Obstet Gynecol. 2011. Vol. 38, N 3. P. 272–280. https://doi.org/10.1002/uog.9093.